Lonhala Magnair Kit is a drug owned by Sumitomo Pharma America Inc. It is protected by 14 US drug patents filed from 2018 to 2022. Out of these, 11 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 07, 2036. Details of Lonhala Magnair Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10744277 | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(12 years from now) | Active |
| US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(11 years from now) | Active |
| US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(10 years from now) | Active |
| US9604018 | Aerosol therapy device |
May, 2033
(8 years from now) | Active |
| US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(7 years from now) | Active |
| US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(5 years from now) | Active |
| US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
Feb, 2029
(4 years from now) | Active |
| US9265900 | Disposable ampoule for an aerosol generating device |
Dec, 2028
(4 years from now) | Active |
| US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug, 2026
(1 year, 8 months from now) | Active |
| US7931212 | Fluid droplet production apparatus and method |
Nov, 2025
(1 year, 9 days from now) | Active |
| US7458372 | Inhalation therapy device |
Nov, 2024
(2 days from now) | Active |
| US8511581 | Fluid droplet production apparatus and method |
Nov, 2023
(1 year, 8 days ago) |
Expired
|
| US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep, 2022
(2 years ago) |
Expired
|
| US6962151 | Inhalation nebulizer |
Oct, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lonhala Magnair Kit's patents.
Latest Legal Activities on Lonhala Magnair Kit's Patents
Given below is the list of recent legal activities going on the following patents of Lonhala Magnair Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Feb, 2024 | US10744277 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2023 | US10688518 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Apr, 2023 | US9168556 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Feb, 2023 | US10376661 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Oct, 2022 | US7931212 |
| Recordation of Patent Grant Mailed Critical | 22 Mar, 2022 | US11278683 |
| Patent Issue Date Used in PTA Calculation Critical | 22 Mar, 2022 | US11278683 |
| Email Notification Critical | 03 Mar, 2022 | US11278683 |
| Issue Notification Mailed Critical | 02 Mar, 2022 | US11278683 |
| Application Is Considered Ready for Issue Critical | 16 Feb, 2022 | US11278683 |
FDA has granted several exclusivities to Lonhala Magnair Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Lonhala Magnair Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Lonhala Magnair Kit.
Exclusivity Information
Lonhala Magnair Kit holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Lonhala Magnair Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Several oppositions have been filed on Lonhala Magnair Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Lonhala Magnair Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Lonhala Magnair Kit patents.
Lonhala Magnair Kit's Oppositions Filed in EPO
Lonhala Magnair Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 12, 2021, by Vectura Limited. This opposition was filed on patent number EP14815314A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14815314A | Feb, 2021 | Vectura Limited | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Lonhala Magnair Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lonhala Magnair Kit's family patents as well as insights into ongoing legal events on those patents.
Lonhala Magnair Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lonhala Magnair Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 07, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lonhala Magnair Kit Generic API suppliers:
Glycopyrrolate is the generic name for the brand Lonhala Magnair Kit. 44 different companies have already filed for the generic of Lonhala Magnair Kit, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lonhala Magnair Kit's generic
Alternative Brands for Lonhala Magnair Kit
Lonhala Magnair Kit which is used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction., has several other brand drugs in the same treatment category and using the same active ingredient (Glycopyrrolate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Glycopyrrolate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Astrazeneca |
| ||
| Astrazeneca Ab |
| ||
| Azurity |
| ||
| Casper Pharma Llc |
| ||
| Merz Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Glycopyrrolate, Lonhala Magnair Kit's active ingredient. Check the complete list of approved generic manufacturers for Lonhala Magnair Kit
About Lonhala Magnair Kit
Lonhala Magnair Kit is a drug owned by Sumitomo Pharma America Inc. It is used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction. Lonhala Magnair Kit uses Glycopyrrolate as an active ingredient. Lonhala Magnair Kit was launched by Sumitomo Pharma Am in 2017.
Approval Date:
Lonhala Magnair Kit was approved by FDA for market use on 05 December, 2017.
Active Ingredient:
Lonhala Magnair Kit uses Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate ingredient
Treatment:
Lonhala Magnair Kit is used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction.
Dosage:
Lonhala Magnair Kit is available in solution form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 25MCG/ML | SOLUTION | Discontinued | INHALATION |